Cost-Utility of Sildenafil for Persistent Pulmonary Hypertension of the Newborn

Author:

Evers Patrick D.1ORCID,Critser Paul J.2,Cash Michelle2,Magness Melissa2,Hoelle Susan2,Hirsch Russel23

Affiliation:

1. Division of Pediatric Cardiology, Oregon Health and Sciences University, Portland, Oregon

2. Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

3. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio

Abstract

Objective While advanced therapies for severe persistent pulmonary hypertension of the newborn (PPHN) such as inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) are standard treatments in high-income countries, these therapies are often unavailable in resource-limited settings such as middle-income countries. However, there are small clinical trials illustrating the efficacy of sildenafil at reducing mortality in PPHN. This analysis sought to determine the cost-utility of enteral sildenafil for the treatment of severe PPHN. Study Design A Markov-state transition model was constructed for the two clinical approaches to compare costs, clinical outcomes, and quality of life: (1) “conventional,” (2) “sildenafil.” The impact of sildenafil was modeled as a relative risk modifier of the conventional strategy's mortality risk. Transitional probabilities, costs, and utility metrics were extracted from the literature. Sensitivity analyses for each model input as well as 100-patient Monte Carlo simulations were used to test the durability of the model conclusion. Results The sildenafil strategy was cost-effective for upper but not lower middle-income countries with an incremental cost-effectiveness ratio of $2,339 per quality-adjusted life year. This conclusion was durable across a wide-range of model assumptions; the sildenafil strategy only failed to meet criteria for cost-effectiveness when sildenafil therapy had a mortality relative risk efficacy of >0.89, if life expectancy in that country is <40 years, or if the lifetime forecasted costs of a survivor's life was quite high. Conclusion Enteral sildenafil is a cost-effective intervention for severe PPHN for upper middle-income countries where ECMO and iNO are not available. Key Points

Publisher

Georg Thieme Verlag KG

Subject

Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health

Reference29 articles.

1. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes;M C Walsh-Sukys;Pediatrics,2000

2. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn;J D Roberts Jr;N Engl J Med,1997

3. Morbidity of persistent pulmonary hypertension of the newborn in the first year of life;M A Steurer;J Pediatr,2019

4. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn;A P Goldman;Pediatrics,1996

5. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn;S A Lorch;Pediatrics,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3